| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | BLUEPRINT MEDICINES CORP COM | 3,255,280 | 91,311,000 | 18.35% | ||
| 2 | CYTOKINETICS INC | 4,851,691 | 58,948,000 | 11.84% | ||
| 3 | CHEMOCENTRYX INC | 7,798,572 | 57,709,000 | 11.59% | ||
| 4 | ARRAY BIOPHARMA INC COM | 4,986,186 | 43,829,000 | 8.81% | ||
| 5 | CONCERT PHARMACEUTICALS INC COM | 2,616,249 | 26,921,000 | 5.41% | ||
| 6 | XENON PHARMACEUTICALS INC | 3,043,805 | 23,437,000 | 4.71% | ||
| 7 | FORWARD PHARMA A/S | 1,387,853 | 20,832,000 | 4.19% | ||
| 8 | CTI BIOPHARMA CORP | 44,796,940 | 18,053,000 | 3.63% | ||
| 9 | COLUCID PHARMACEUTICALS INC COM | 484,335 | 17,630,000 | 3.54% | ||
| 10 | GLYCOMIMETICS INC | 2,826,282 | 17,240,000 | 3.46% | ||
| 11 | ONCOMED PHARMACEUTICALS INC | 1,760,489 | 13,573,000 | 2.73% | ||
| 12 | CASCADIAN THERAPEUTICS | 3,133,224 | 13,504,000 | 2.71% | ||
| 13 | INFINITY PHARMACEUTICALS INC COM | 7,860,808 | 10,612,000 | 2.13% | ||
| 14 | ACHILLION PHARMACEUTICALS INC COM | 2,423,300 | 10,008,000 | 2.01% | ||
| 15 | FATE THERAPEUTICS INC COM | 3,759,398 | 9,436,000 | 1.90% | ||
| 16 | ArQule Inc | 7,400,128 | 9,324,000 | 1.87% | ||
| 17 | Esperion Therapeutics Inc | 712,770 | 8,924,000 | 1.79% | ||
| 18 | ADURO BIOTECH | 745,886 | 8,503,000 | 1.71% | ||
| 19 | IMMUNE DESIGN CORP COM | 1,320,164 | 7,261,000 | 1.46% | ||
| 20 | CYTOMX THERAPEUTICS INC COM | 554,806 | 6,097,000 | 1.22% | ||
| 21 | GTX INC DEL COM NEW | 1,108,433 | 5,853,000 | 1.18% | ||
| 22 | Sunesis Pharmaceuticals, Inc. | 1,392,720 | 5,042,000 | 1.01% | ||
| 23 | Nivalis Therapeutics Inc | 1,864,474 | 4,176,000 | 0.84% | ||
| 24 | OREXIGEN THERAPEUTICS INC | 10,000,000 | 3,000,000 | 0.60% | PRN | |
| 25 | Pieris Pharmaceuticals | 1,854,768 | 2,606,000 | 0.52% | ||
| 26 | PAIN THERAPEUTICS INC | 2,278,552 | 1,299,000 | 0.26% | ||
| 27 | OREXIGEN THERAPEUTICS INC | 734,976 | 1,279,000 | 0.26% | ||
| 28 | XOMA CORP | 302,800 | 1,278,000 | 0.26% | ||
| 29 | ANTHERA PHARMACEUTICALS I | 62,292 | 40,000 | 0.01% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000921895-17-000368, filed 2017.02.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
